Figure 3.
Figure 3. HLA class I antigen expression by immunomagnetic isolated myeloid leukemic and autologous normal myeloid cells. Untouched autologous normal cells (top row) were stained with anti-CD3 (black) and anti-CD33 (white) mAbs (A); anti–HLA-A mAb LGIII-147.4.2 (open, solid line), anti–HLA-B mAb B1.23.2 (black), and control mAb (open, dotted line) (B); and with anti–HLA-A, -B, -C mAb W6/32 (black) and control mAb (white) (C). Untouched leukemic cells from a patient with AML (bottom row) were stained with anti-CD3 (white) and anti-CD33 (black) mAbs (D); anti–HLA-A mAb LGIII-147.4.2 (open, solid line), anti–HLA-B mAb B1.23.2 (black), and control mAb (open, dotted line) (E); and with anti–HLA-A, -B, -C mAb W6/32 (black) and control mAb (white) (F). Forward/side scatter dot plots of the isolated cell populations are shown on the left.

HLA class I antigen expression by immunomagnetic isolated myeloid leukemic and autologous normal myeloid cells. Untouched autologous normal cells (top row) were stained with anti-CD3 (black) and anti-CD33 (white) mAbs (A); anti–HLA-A mAb LGIII-147.4.2 (open, solid line), anti–HLA-B mAb B1.23.2 (black), and control mAb (open, dotted line) (B); and with anti–HLA-A, -B, -C mAb W6/32 (black) and control mAb (white) (C). Untouched leukemic cells from a patient with AML (bottom row) were stained with anti-CD3 (white) and anti-CD33 (black) mAbs (D); anti–HLA-A mAb LGIII-147.4.2 (open, solid line), anti–HLA-B mAb B1.23.2 (black), and control mAb (open, dotted line) (E); and with anti–HLA-A, -B, -C mAb W6/32 (black) and control mAb (white) (F). Forward/side scatter dot plots of the isolated cell populations are shown on the left.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal